FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137415795> ?p ?o ?g. }

• W2137415795 endingPage "1138" @default.
• W2137415795 startingPage "1130" @default.
• W2137415795 abstract "Abstract Objectives To assess LDL subfraction phenotype and lipoprotein-associated phospholipase A2 (Lp-PLA2) in naive HIV-infected patients starting atazanavir/ritonavir or darunavir/ritonavir plus tenofovir/emtricitabine. Methods This was a substudy of a multicentre randomized study. Standard lipid parameters, LDL subfraction phenotype (by gradient gel electrophoresis) and Lp-PLA2 activity (by 2-thio-PAF) were measured at baseline and weeks 24 and 48. Multivariate regression analysis was performed. Results are expressed as the median (IQR). Results Eighty-six (atazanavir/ritonavir, n = 45; darunavir/ritonavir, n = 41) patients were included: age 36 (31–41) years; 89% men; CD4 319 (183–425) cells/mm3; and Framingham score 1% (0%–2%). No differences in demographics or lipid measurements were found at baseline. At week 48, a mild but significant increase in total cholesterol and HDL-cholesterol was observed in both arms, whereas LDL cholesterol increased only in the darunavir/ritonavir arm and triglycerides only in the atazanavir/ritonavir arm. The apolipoprotein A-I/apolipoprotein B ratio increased only in the atazanavir/ritonavir arm. At week 48, the LDL subfraction phenotype improved in the darunavir/ritonavir arm (increase in LDL particle size and in large LDL particles), whereas it worsened in the atazanavir/ritonavir arm (increase in small and dense LDL particles, shift to a greater prevalence of phenotype B); the worsening was related to the greater increase in triglycerides in the atazanavir/ritonavir arm. No changes in total Lp-PLA2 activity or relative distribution in LDL or HDL particles were found at week 48 in either arm. Conclusions In contrast with what occurred in the atazanavir/ritonavir arm, the LDL subfraction phenotype improved with darunavir/ritonavir at week 48. This difference was associated with a lower impact on plasma triglycerides with darunavir/ritonavir." @default.
• W2137415795 created "2016-06-24" @default.
• W2137415795 creator A5001003748 @default.
• W2137415795 creator A5001557481 @default.
• W2137415795 creator A5004612964 @default.
• W2137415795 creator A5012384912 @default.
• W2137415795 creator A5016792188 @default.
• W2137415795 creator A5020210842 @default.
• W2137415795 creator A5037240373 @default.
• W2137415795 creator A5046681997 @default.
• W2137415795 creator A5053140952 @default.
• W2137415795 creator A5058557146 @default.
• W2137415795 creator A5072944678 @default.
• W2137415795 creator A5081538828 @default.
• W2137415795 date "2014-12-23" @default.
• W2137415795 modified "2023-10-18" @default.
• W2137415795 title "Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study" @default.
• W2137415795 cites W1561009390 @default.
• W2137415795 cites W2001105266 @default.
• W2137415795 cites W2001878661 @default.
• W2137415795 cites W2011361600 @default.
• W2137415795 cites W2013975989 @default.
• W2137415795 cites W2014391765 @default.
• W2137415795 cites W2021271479 @default.
• W2137415795 cites W2047324685 @default.
• W2137415795 cites W2049969210 @default.
• W2137415795 cites W2050657579 @default.
• W2137415795 cites W2053038300 @default.
• W2137415795 cites W2053139723 @default.
• W2137415795 cites W2060139450 @default.
• W2137415795 cites W2073738273 @default.
• W2137415795 cites W2076339980 @default.
• W2137415795 cites W2101333957 @default.
• W2137415795 cites W2114408062 @default.
• W2137415795 cites W2116717181 @default.
• W2137415795 cites W2132235918 @default.
• W2137415795 cites W2133045932 @default.
• W2137415795 cites W2141230205 @default.
• W2137415795 cites W2144518502 @default.
• W2137415795 cites W2153777696 @default.
• W2137415795 cites W2154702233 @default.
• W2137415795 cites W2165539109 @default.
• W2137415795 cites W2165884492 @default.
• W2137415795 cites W2168402817 @default.
• W2137415795 cites W2323323105 @default.
• W2137415795 cites W4230870013 @default.
• W2137415795 doi "https://doi.org/10.1093/jac/dku501" @default.
• W2137415795 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25538166" @default.
• W2137415795 hasPublicationYear "2014" @default.
• W2137415795 type Work @default.
• W2137415795 sameAs 2137415795 @default.
• W2137415795 citedByCount "18" @default.
• W2137415795 countsByYear W21374157952014 @default.
• W2137415795 countsByYear W21374157952015 @default.
• W2137415795 countsByYear W21374157952016 @default.
• W2137415795 countsByYear W21374157952017 @default.
• W2137415795 countsByYear W21374157952018 @default.
• W2137415795 countsByYear W21374157952019 @default.
• W2137415795 countsByYear W21374157952020 @default.
• W2137415795 countsByYear W21374157952021 @default.
• W2137415795 countsByYear W21374157952022 @default.
• W2137415795 crossrefType "journal-article" @default.
• W2137415795 hasAuthorship W2137415795A5001003748 @default.
• W2137415795 hasAuthorship W2137415795A5001557481 @default.
• W2137415795 hasAuthorship W2137415795A5004612964 @default.
• W2137415795 hasAuthorship W2137415795A5012384912 @default.
• W2137415795 hasAuthorship W2137415795A5016792188 @default.
• W2137415795 hasAuthorship W2137415795A5020210842 @default.
• W2137415795 hasAuthorship W2137415795A5037240373 @default.
• W2137415795 hasAuthorship W2137415795A5046681997 @default.
• W2137415795 hasAuthorship W2137415795A5053140952 @default.
• W2137415795 hasAuthorship W2137415795A5058557146 @default.
• W2137415795 hasAuthorship W2137415795A5072944678 @default.
• W2137415795 hasAuthorship W2137415795A5081538828 @default.
• W2137415795 hasBestOaLocation W21374157951 @default.
• W2137415795 hasConcept C126322002 @default.
• W2137415795 hasConcept C134018914 @default.
• W2137415795 hasConcept C142462285 @default.
• W2137415795 hasConcept C159047783 @default.
• W2137415795 hasConcept C185592680 @default.
• W2137415795 hasConcept C2778163477 @default.
• W2137415795 hasConcept C2778414717 @default.
• W2137415795 hasConcept C2779182219 @default.
• W2137415795 hasConcept C2779298103 @default.
• W2137415795 hasConcept C2993143319 @default.
• W2137415795 hasConcept C3013748606 @default.
• W2137415795 hasConcept C62746215 @default.
• W2137415795 hasConcept C71924100 @default.
• W2137415795 hasConcept C90924648 @default.
• W2137415795 hasConcept C98274493 @default.
• W2137415795 hasConceptScore W2137415795C126322002 @default.
• W2137415795 hasConceptScore W2137415795C134018914 @default.
• W2137415795 hasConceptScore W2137415795C142462285 @default.
• W2137415795 hasConceptScore W2137415795C159047783 @default.
• W2137415795 hasConceptScore W2137415795C185592680 @default.
• W2137415795 hasConceptScore W2137415795C2778163477 @default.
• W2137415795 hasConceptScore W2137415795C2778414717 @default.
• W2137415795 hasConceptScore W2137415795C2779182219 @default.

• next